Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: Angel Medina who wrote (2977)	3/26/1999 9:58:00 PM
From: Angel Medina	Read Replies (1) \| Respond to of 3725

To Imatron investors: This will be a long week end !! Or maybe a very long next week. A one-two punch to my investments in Imatron. First, bad earnings will be issued by the company Monday morning. Second, the new cheaper approach to scans, which precludes the use of ultra fast CT. That is not a good combination to make Imat stock go up on Monday, that's for sure.

To: Angel Medina who wrote (2977)	3/27/1999 12:11:00 AM
From: Bruce Rozenblit	Read Replies (1) \| Respond to of 3725

Cancel my order for the Valium. Call the mortician. We're dead. I have been pounding my drum for close to two years now that the machine has to be reconfigured to make it cheaper so people can afford to buy it. I am not overly presumptuous or a self appointed know it all. I'm an engineer and understand the flow and growth of technology. One of the truest statements of all is "there are many ways to skin a cat". This new application just might be one of them. There are dozens of ways to functionally, mechanically, and electrically, reconfigure the scanner. I suspect the machine is as it is because its Boyd's little baby and he wants it the way he he wants it. In the high tech product development business, you have to be prepared to eat your children. That is precisely what Intel does. It appears that Imatron has succeeded in proving to the world that calcium screening for CAD is useful and beneficial. I am convinced that most of the resistance to EBCT is because of the high capitol cost. If the equipment cost less, then watch folks, all of the sudden calcium screening will be the cool thing to do. It can be an additional revenue stream for existing CT machines. IF calcium screening becomes an accepted diagnostic tool, that is very good. BUT EBCT has to offer better performance at equal cost or no one will buy it. If Imatron had already established a strong sales base then they could fight off a lower cost threat, for a while. As it is the market is wide open and Imatron has no dominance. Topping off our predicament, I have no faith in management.